microscopic skin tissue column grafting technique using the autologous regeneration of tissue system

Conditions: Wound of Skin; Burns

Summary: this study evaluates microscopic skin tissue column (mstc) grafting technique using the autologous regeneration tissue (art) system in the treatment of skin loss. each participant will have three study treated areas, the three treatments include: 1. traditional grafting, 2. high density mstc, 3. low density mstc.

the current standard of care for coverage of large open wounds is split-thickness skin graft (stsg). these stsgs are typically harvested with a dermatome, which tangentially removes the epidermis and a thin layer of dermis from a healthy donor site. while relatively versatile, there are important limitations to stsgs. first, a healthy and readily accessible donor site is required prior to grafting. second, each donor site itself becomes an open wound and is unable for grafting for approximately two weeks as the wound heals. to facilitate wound coverage, harvested stsg can be meshed up to a rate of 6:1 (though more common ratios are 1:1 and 2:1). however, widely meshed grafts tend to produce more severe scars and contractures, which represent tremendous long-term morbidity to the patient. the only means to avoid using widely meshed grafts is to harvest additional healthy donor skin, resulting in more pain from larger wound burdens and disfiguring scars in previously uninjured regions. finally, stsg does not include deeper dermal structures such as hair follicles and sweat glands, and as such these grafts are both functionally and aesthetically substandard. recently, skin microcolumn grafting has been proposed to address both skin graft donor site morbidity and long-term graft contracture. specifically, the autologous regeneration of tissue (art)tm system, an fda-cleared device, harvests full-thickness microscopic skin tissue columns (mstc) orthogonally instead of tangentially; each skin column includes epidermis, dermis and associated adnexal structures, and subcutaneous fat. these mstc cover an area up to 10x larger than the donor site (100:1 ratio, compared to up to 6:1 using stsg). inclusion of adnexal structures results in improved wound-healing quality, less scarring, and a lower rate of secondary contracture. the small wounds caused by the art system at the donor site during mstc harvesting heal quickly and without the comorbidities associated with traditional harvesting. this autologous approach maintains low immunogenicity as no foreign or synthetic tissue is used as a skin substitute, which decreases the chance of infection or rejection in the wound bed. in short, the art system allows for expansion of a donor site to a ratio of 1:100, faster healing of the donor site while still preserving donor site function, and improved healing of the original wound. the investigators will conduct a prospective, randomized controlled clinical trial comparing the mstc grafting technique to the standard of care. treatment sites will be randomized to either receiving mstc or the traditional stsg. objective measurements and assessments will be completed during subject follow-ups visits for up to six months.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 and age less than or equal to 70. * skin loss from surgery, trauma, and/or burns. * presence of one uniform contiguous wound ≥150cm2 * sufficient non-injured healthy skin from which conventional stsg can be harvested to cover study and non-study sites. * sufficient non-injured healthy skin from which the study device can be used to harvest mstc to cover the study sites. * study donor site has not been previously harvested. * able and likely to follow-up, to have three consecutive appointments and appear for 6 month follow up visit. * subject agrees to abstain from enrollment in any other interventional clinical trial while enrolled in this study. exclusion criteria: * exposure of tendon, bone devoid of peritenon or periosteum, or other structures deemed non-graftable by the treating physician or study investigator. * concomitant skin disease/infection at the recipient or donor sites. * use of topical steroid, anti-metabolite, or other pharmacologic therapy on study site. * use of systemic steroids in the past month. * concurrent conditions that in the opinion of the investigator may compromise subject safety, study objectives or wound healing. * current recipient of immunosuppressive therapy. * current treatment with medication that inhibit/compromise wound healing. * known history of malignancy. * pregnancy or lactation * prisoner * history of noncompliance -\>40% total body surface area involvement.